Global Market Insights, Inc. - logo

Pet Cancer Therapeutics Market Size By Medicine Type (Chemotherapy Drugs and Vaccines), By Species (Dogs and Cats), By Cancer Type (Lymphoma, Mast Cell Cancer Tumors, Melanoma, Mammary and Squamous Cell Cancer), Regional Outlook (U.S., Canada, Germany, UK, Spain, Italy, France, China, Japan, India, Australia, Brazil, Mexico), Technology Development, Competitive Landscape & Forecast, 2017 – 2024

Published Date: August 2017 | 95 Pages | Report ID: GMI2017 Report Format: PDF

Inquiry Before Buying   Request Sample

Report Content

Chapter 1.    Methodology

1.1. Methodology

1.1.1. Initial data exploration

1.1.2. Statistical model and forecast

1.1.3. Industry insights and validation

1.1.4. Market definition & forecast parameters

1.2. Data sources

1.2.1. Secondary

1.2.2. Primary

Chapter 2.    Executive Summary

2.1. Pet cancer therapeutics market 3600 synopsis, 2013 –2024

2.1.1. Business trends

2.1.2. Medicine type trends

2.1.3. Species trends

2.1.4. Cancer type trends

2.1.5. Regional trends

Chapter 3.    Pet cancer therapeutics Industry Insights

3.1. Industry segmentation

3.2. Industry size and forecast, 2013 - 2024

3.3. Industry impact forces

3.3.1. Growth drivers

3.3.1.1. Rising number of pets’ population

3.3.1.2.    Increasing prevalence of cancer in pets

3.3.1.3.    Rising willingness of pet owners to spend on pet healthcare

3.3.1.4.    Increasing number of new product development

3.3.2. Industry pitfalls & challenges

3.3.2.1. Side-effects of Pet cancer therapeutics

3.3.2.2.    Dearth of veterinary oncologist

3.3.2.3.    Low out of pocket expenditure on pet healthcare in developing countries

3.4. Regulatory landscape

3.4.1. U.S.

3.4.2. Europe

3.5. Technology landscape

3.5.1. North America

3.5.2. Europe

3.6. Pipeline analysis

3.7. Growth potential analysis

3.8. Porter's analysis

3.9. Competitive landscape, 2016

3.10.      PESTEL analysis

Chapter 4.    Pet cancer therapeutics Market, By Medicine Type

4.1. Pet cancer therapeutics market share, by drug category, 2016 & 2024

4.2. Chemotherapy drugs

4.2.1. Market estimates and forecast, by region, 2013 - 2024

4.3. Vaccines

4.3.1. Market estimates and forecast, by region, 2013 - 2024

Chapter 5.    Pet cancer therapeutics Market, By Species

5.1. Pet cancer therapeutics market share by species, 2016 & 2024

5.2. Dogs

5.2.1. Market estimates and forecast, by region, 2013–2024

5.3. Cats

5.3.1. Market estimates and forecast, by region, 2013–2024

Chapter 6.    Pet cancer therapeutics Market, By Cancer Type

6.1. Pet cancer therapeutics market share by cancer type, 2016 & 2024

6.2. Lymphoma

6.2.1. Market estimates and forecast, by region, 2013–2024

6.3. Mast Cell Cancer

6.3.1. Market estimates and forecast, by region, 2013–2024

6.4. Melanoma

6.4.1. Market estimates and forecast, by region, 2013–2024

6.5. Mammary and Squamous Cell Cancer

6.5.1. Market estimates and forecast, by region, 2013–2024

6.6. Others

6.6.1. Market estimates and forecast, by region, 2013–2024

Chapter 7.    Pet cancer therapeutics Market, By Region

7.1. Pet cancer therapeutics market share by region, 2016 & 2024

7.2. North America

7.2.1. Market estimates and forecast, by country, 2013 - 2024

7.2.2. Market estimates and forecast, by medicine type, 2013 – 2024

7.2.3. Market estimates and forecast, by species, 2013 - 2024

7.2.4. Market estimates and forecast, by cancer type, 2013 - 2024

7.2.5. U.S.

7.2.5.1.  Market estimates and forecast, by medicine type, 2013 – 2024

7.2.5.2.    Market estimates and forecast, by species, 2013 - 2024

7.2.5.3.    Market estimates and forecast, by cancer type, 2013 - 2024

7.2.6. Canada

7.2.6.1.  Market estimates and forecast, by medicine type, 2013 – 2024

7.2.6.2.    Market estimates and forecast, by species, 2013 - 2024

7.2.6.3.    Market estimates and forecast, by cancer type, 2013 - 2024

7.3. Europe      

7.3.1. Market estimates and forecast, by country, 2013 - 2024

7.3.2. Market estimates and forecast, by medicine type, 2013 – 2024

7.3.3. Market estimates and forecast, by species, 2013 - 2024

7.3.4. Market estimates and forecast, by cancer type, 2013 - 2024

7.3.5. Germany

7.3.5.1.  Market estimates and forecast, by medicine type, 2013 – 2024

7.3.5.2.    Market estimates and forecast, by species, 2013 - 2024

7.3.5.3.    Market estimates and forecast, by cancer type, 2013 - 2024

7.3.6. UK

7.3.6.1.  Market estimates and forecast, by medicine type, 2013 – 2024

7.3.6.2.    Market estimates and forecast, by species, 2013 - 2024

7.3.6.3.    Market estimates and forecast, by cancer type, 2013 - 2024

7.3.7. France

7.3.7.1.  Market estimates and forecast, by medicine type, 2013 – 2024

7.3.7.2.    Market estimates and forecast, by species, 2013 - 2024

7.3.7.3.    Market estimates and forecast, by cancer type, 2013 - 2024

7.3.8. Spain

7.3.8.1.  Market estimates and forecast, by medicine type, 2013 – 2024

7.3.8.2.    Market estimates and forecast, by species, 2013 - 2024

7.3.8.3.    Market estimates and forecast, by cancer type, 2013 - 2024

7.3.9. Italy

7.3.9.1.  Market estimates and forecast, by medicine type, 2013 – 2024

7.3.9.2.    Market estimates and forecast, by species, 2013 - 2024

7.3.9.3.    Market estimates and forecast, by cancer type, 2013 - 2024

7.4. Asia Pacific

7.4.1. Market estimates and forecast, by country, 2013 - 2024

7.4.2. Market estimates and forecast, by medicine type, 2013 – 2024

7.4.3. Market estimates and forecast, by species, 2013 - 2024

7.4.4. Market estimates and forecast, by cancer type, 2013 - 2024

7.4.5. China

7.4.5.1.  Market estimates and forecast, by medicine type, 2013 – 2024

7.4.5.2.    Market estimates and forecast, by species, 2013 - 2024

7.4.5.3.    Market estimates and forecast, by cancer type, 2013 - 2024

7.4.6. India

7.4.6.1.  Market estimates and forecast, by medicine type, 2013 – 2024

7.4.6.2.    Market estimates and forecast, by species, 2013 - 2024

7.4.6.3.    Market estimates and forecast, by cancer type, 2013 - 2024

7.4.7. Japan

7.4.7.1.  Market estimates and forecast, by medicine type, 2013 – 2024

7.4.7.2.    Market estimates and forecast, by species, 2013 - 2024

7.4.7.3.    Market estimates and forecast, by cancer type, 2013 - 2024

7.4.8. Australia

7.4.8.1.  Market estimates and forecast, by medicine type, 2013 – 2024

7.4.8.2.    Market estimates and forecast, by species, 2013 - 2024

7.4.8.3.    Market estimates and forecast, by cancer type, 2013 - 2024

7.5. Latin America

7.5.1. Market estimates and forecast, by country, 2013 - 2024

7.5.2. Market estimates and forecast, by medicine type, 2013 – 2024

7.5.3. Market estimates and forecast, by species, 2013 - 2024

7.5.4. Market estimates and forecast, by cancer type, 2013 - 2024

7.5.5. Brazil

7.5.5.1.  Market estimates and forecast, by medicine type, 2013 – 2024

7.5.5.2.    Market estimates and forecast, by species, 2013 - 2024

7.5.5.3.    Market estimates and forecast, by cancer type, 2013 - 2024

7.5.6. Mexico

7.5.6.1.  Market estimates and forecast, by medicine type, 2013 – 2024

7.5.6.2.    Market estimates and forecast, by species, 2013 - 2024

7.5.6.3.    Market estimates and forecast, by cancer type, 2013 - 2024

Chapter 8.    Company Profiles

8.1. Zoetis

8.1.1. Business Overview

8.1.2. Financial Data

8.1.3. Product Landscape

8.1.4. Strategic Outlook

8.1.5. SWOT analysis

8.2. Merial

8.2.1. Business Overview

8.2.2. Financial Data

8.2.3. Product Landscape

8.2.4. Strategic Outlook

8.2.5. SWOT analysis

8.3. Aratana Therapeutics

8.3.1. Business Overview

8.3.2. Financial Data

8.3.3. Product Landscape

8.3.4. Strategic Outlook

8.3.5. SWOT analysis

8.4. AB Science

8.4.1. Business Overview

8.4.2. Financial Data

8.4.3. Product Landscape

8.4.4. Strategic Outlook

8.4.5. SWOT analysis

8.5. vetivax

8.5.1. Business Overview

8.5.2. Financial Data

8.5.3. Product Landscape

8.5.4. Strategic Outlook

8.5.5. SWOT analysis

8.6. Oasmia Pharmaceutical

8.6.1. Business Overview

8.6.2. Financial Data

8.6.3. Product Landscape

8.6.4. Strategic Outlook

8.6.5. SWOT analysis

8.7. VetDC

8.7.1. Business Overview

8.7.2. Financial Data

8.7.3. Product Landscape

8.7.4. Strategic Outlook

8.7.5. SWOT analysis

8.8. Regeneus.

8.8.1. Business Overview

8.8.2. Financial Data

8.8.3. Product Landscape

8.8.4. Strategic Outlook

8.8.5. SWOT analysis

8.9. CanFel Therapeutics

8.9.1. Business Overview

8.9.2. Financial Data

8.9.3. Product Landscape

8.9.4. Strategic Outlook

8.9.5. SWOT analysis

8.10. Karyopharms Verdinexor

8.10.1. Business Overview

8.10.2.  Financial Data

8.10.3.  Product Landscape

8.10.4.  Strategic Outlook

8.10.5.  SWOT analysis

 

Data Tables

TABLE 1.    Pet cancer therapeutics industry 3600 synopsis, 2013 – 2024

TABLE 2.    Pet cancer therapeutics market, 2013 – 2024 (USD Million)

TABLE 3.    Pet cancer therapeutics market, by medicine type, 2013 – 2024(USD Million)

TABLE 4.    Pet cancer therapeutics market, by species, 2013 – 2024(USD Million)

TABLE 5.    Pet cancer therapeutics market, by cancer type, 2013 – 2024(USD Million)

TABLE 8.    Industry impact forces

TABLE 9.    Pet cancer therapeutics market, by medicine type, chemotherapy drugs, by region 2013 - 2024 (USD Million)

TABLE 10.  Pet cancer therapeuticsmarket, by medicine type, vaccines, by region 2013 - 2024 (USD Million)

TABLE 11.  Pet cancer therapeutics market, by species, dogs, by region 2013 - 2024 (USD Million)

TABLE 12.  Pet cancer therapeutics market, by species, cats, by region 2013 - 2024 (USD Million)

TABLE 13.  Pet cancer therapeutics market, by cancer type, lymphoma by region 2013 - 2024 (USD Million)

TABLE 14.  Pet cancer therapeutics market, by cancer type, mast cell cancer, by region 2013 - 2024 (USD Million)

TABLE 15.  Pet cancer therapeutics market, by cancer type, melanoma, by region 2013 - 2024 (USD Million)

TABLE 16.  Pet cancer therapeutics market, by cancer type, mammary and squamous cell cancer, by region 2013 - 2024 (USD Million)

TABLE 17.  North America pet cancer therapeutics market, by country 2013 - 2024 (USD Million) 

TABLE 18.  North America pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 19.  North America pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 20.  North America pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 21.  U.S. pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 22.  U.S. pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 23.  U.S. pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 24.  Canada pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 25.  Canada pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 26.  Canada pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 27.  Europe pet cancer therapeutics market, by country 2013 - 2024 (USD Million)

TABLE 28.  Europe pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 29.  Europe pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 30.  Europe pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 31.  Germany pet cancer therapeutics market, medicine type , 2013 - 2024 (USD Million)

TABLE 32.  Germany pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 33.  Germany pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 34.  UK pet cancer therapeutics market, by medicine, 2013 - 2024 (USD Million)

TABLE 35.  UK pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 36.  UK pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 37.  France pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 38.  France pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 39.  France pet cancer therapeutics market, cancer type, 2013 - 2024 (USD Million)

TABLE 40.  Spain pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 41.  Spain pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 42.  Spain pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 43.  Italy pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 44.  Italy pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 45.  Italy pet cancer therapeuticsmarket, by cancer type, 2013 - 2024 (USD Million)

TABLE 46.  Rest of Europe pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 47.  Rest of Europe pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 48.  Rest of Europe pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 49.  Asia Pacific pet cancer therapeutics market, by country 2013 - 2024 (USD Million)     

TABLE 50.  Asia Pacific pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 51.  Asia Pacific pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 52.  Asia Pacific pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 53.  China pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 54.  China pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 55.  China pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 56.  India pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 57.  India pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 58.  India pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 59.  Japan pet cancer therapeuticsmarket, by medicine type, 2013 - 2024 (USD Million)

TABLE 60   Japan pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 61.  Japan pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 62.  Australia pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 63.  Australia pet cancer therapeutics market, by species , 2013 - 2024 (USD Million)

TABLE 64.  Australia pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 65.  Rest of Asia pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 66.  Rest of Asia pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 67.  Rest of Asia pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 68.  Latin America pet cancer therapeutics market, by country 2013 - 2024 (USD Million)  

TABLE 69.  Latin America pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 70.  Latin America pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 71.  Latin America pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 72.  Brazil pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 73.  Brazil pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 74.  Brazil  pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 75.  Mexico pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 76.  Mexico pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 77.  Mexico pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

TABLE 78.  Rest of LATAM pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

TABLE 79   Rest of LATAM pet cancer therapeutics market, by species, 2013 - 2024 (USD Million)

TABLE 80.  Rest of LATAM pet cancer therapeutics market, by cancer type, 2013 - 2024 (USD Million)

 

Charts & Figures

FIG. 1   Industry segmentation

FIG. 2   Pet cancer therapeutics market, 2013- 2024 (USD Million)

FIG. 3   Growth potential analysis

FIG. 4   Porter’s analysis

FIG. 5   PESTEL analysis

FIG. 6   Pet cancer therapeutics market share by medicine type, 2016 & 2024

FIG. 7   Pet cancer therapeutics market share by species, 2016 & 2024

FIG. 8   Pet cancer therapeutics market share by cancer type, 2016 & 2024

FIG. 9   Pet cancer therapeutics market share, by region, 2016 & 2024

Why Global Market Insights?

 Comprehensive Research
  • All-inclusive coverage
  • In-depth and granular data (ex: information for 8 to 15 countries, with clients open to add to this list, in each report)
  • Penetrative insights & latest trends
  • Offers holistic understanding of the market
 Data Accuracy & Reliability
  • Unique methodology
  • Iterative in nature to eliminate errors
  • Detailed methodology, scope, assumptions and data sources available for reference
 Post-Sales Support
  • Committed to making a positive difference for our clients
  • Given the nature of this industry, we are committed to ensure that our clients get maximum return on their investment in our services
  • Every purchase comes with an option to obtain additional information:
    • up to 10% of the original cost
    • 45-minute analyst tele-call to obtain further clarity on the market.
 Security & Confidentiality
  • Global Market Insights, Inc. strictly adheres to PCI-DSS security norms.
  • Only PCI-DSS compliant payment methods used for highest level of client data security

Tailor this report

Customize this report to suit your needs, speak to our research team to avail these benefits


Connect with our sales team